We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.34B
1-Year Est. Return
204.53%
This Fund
S&P 500
This Quarter
Est. Return
+39.96%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.39B
AUM Growth
+$509M
(+18%)
Cap. Flow
-$110M
Cap. Flow
% of AUM
-3.26%
Top 10 Holdings %
Top 10 Hldgs %
67.93%
Holding
88
New
8
Increased
10
Reduced
15
Closed
11
Top Buys
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$99.2M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$75.1M |
| 3 |
Gossamer Bio
GOSS
|
+$51.6M |
| 4 |
Kymera Therapeutics
KYMR
|
+$21M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$13.5M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$118M |
| 2 |
Revolution Medicines
RVMD
|
+$54.4M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$53.7M |
| 4 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$43.5M |
| 5 |
argenx
ARGX
|
+$39.8M |
Sector Composition
| 1 | Healthcare | 99.31% |
| 2 | Financials | 0.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$443M
| $702M | 20.74% |
11,584,280
| – | – |
|
|
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
| $354M | 10.45% |
5,183,431
| – | – |
|
3
Sarepta Therapeutics
SRPT
$1.86B
| $332M | 9.79% |
2,999,453
+131,308
| +5% | +$13.2M |
|
4
AnaptysBio
ANAB
$1.65B
| $192M | 5.66% |
7,521,024
| – | – |
|
5
Arvinas
ARVN
$535M
| $139M | 4.1% |
3,123,300
| – | – |
|
6
Xencor
XNCR
$1.11B
| $137M | 4.05% |
5,282,516
+100
| +0% | +$2.86K |
|
|
LKFT
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
| $136M | 4.03% |
3,197,500
| – | – |
|
|
MORF
8
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $112M | 3.3% |
3,951,566
| – | – |
|
|
SWTX
9
DELISTED
SpringWorks Therapeutics
SWTX
| $98.7M | 2.91% |
+3,460,208
| New | +$99.2M |
|
10
Acadia Pharmaceuticals
ACAD
$4.43B
| $98M | 2.89% |
5,991,479
| – | – |
|
11
Relay Therapeutics
RLAY
$4.25B
| $93.1M | 2.75% |
4,163,824
+440,283
| +12% | +$9.66M |
|
12
Kura Oncology
KURA
$1.01B
| $90.7M | 2.68% |
6,638,371
| – | – |
|
|
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $70.9M | 2.09% |
+1,015,572
| New | +$75.1M |
|
14
Zai Lab
ZLAB
$2.3B
| $69.4M | 2.05% |
2,030,252
-401,633
| -17% | -$17.2M |
|
|
15
Gossamer Bio
GOSS
$81M
| $49.8M | 1.47% |
+4,160,887
| New | +$51.6M |
|
16
Allogene Therapeutics
ALLO
$659M
| $48.5M | 1.43% |
4,488,200
| – | – |
|
|
RNAM
17
DELISTED
Avidity Biosciences
RNAM
| $47.3M | 1.4% |
2,899,285
+139,780
| +5% | +$2.67M |
|
18
Design Therapeutics
DSGN
$846M
| $42.1M | 1.24% |
2,519,268
-114,910
| -4% | -$2.29M |
|
|
SGEN
19
DELISTED
Seagen Inc. Common Stock
SGEN
| $39.1M | 1.15% |
285,793
-722,835
| -72% | -$118M |
|
20
Alector
ALEC
$167M
| $38.4M | 1.13% |
4,056,548
| – | – |
|
|
21
Revolution Medicines
RVMD
$39.1B
| $35.5M | 1.05% |
1,801,847
-2,476,222
| -58% | -$54.4M |
|
22
Atea Pharmaceuticals
AVIR
$389M
| $35.2M | 1.04% |
6,184,861
-155,778
| -2% | -$1.19M |
|
23
Edgewise Therapeutics
EWTX
$4.38B
| $34.4M | 1.01% |
3,493,194
+1,133,386
| +48% | +$11.5M |
|
|
TSVT
24
DELISTED
2seventy bio
TSVT
| $34.1M | 1.01% |
2,341,313
-1,154,630
| -33% | -$17.1M |
|
25
Nuvation Bio
NUVB
$2.05B
| $31.1M | 0.92% |
13,896,543
| – | – |
|
Similar funds
G
MC
BAM
CC
HFM
NO
ST
MFAM